Cardiology: Treatment of Systolic Heart Failure in the Elderly: An Evidence-Based Review

Abstract

Spanish

French

Objective:

To review relevant literature supporting the use of β-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, digoxin, aldosterone antagonists, and vasodilators in the management of heart failure in an elderly patient population aged ≥65 years.

Data Sources:

PubMed, EMBASE, and MEDLINE searches (January 1960–April 2010) were utilized to identify primary literature using the key terms heart failure, treatment, and elderly. Additionally, reference citations from publications identified were utilized, as well as the American College of Cardiology/American Heart Association (ACC/AHA) Guidelines for the Diagnosis and Management of Chronic Heart Failure in the Adult.

Study Selection and Data Extraction:

Primary and tertiary literature, including subgroup analyses, published in English and relating to the use of pharmacotherapy in the treatment of systolic heart failure in the elderly was reviewed.

Data Synthesis:

The aging of the US population is creating a higher prevalence of systolic heart failure in the elderly. Most clinical trials have established the mortality and morbidity benefit of pharmacotherapy in heart failure in nonelderly patients; however, the current ACC/AHA guidelines do not clearly delineate this benefit in persons ≥65 years of age.

Conclusions:

Clinical trial data, based on limited numbers of individuals aged ≥65 years, suggest that use of β-blockers, ACE inhibitors, ARBs, aldosterone antagonists, and vasodilators (hydralazine/nitrates) have similar mortality benefit to that observed in younger patients. As supported in the ACC/AHA guidelines, these agents should be prescribed with clinical judgment to all elderly patients, with close monitoring for adverse events. Future clinical trials with greater inclusion of patients ≥65 years will help to elucidate the magnitude of benefits of optimal pharmacotherapy on mortality and morbidity rates in this population.

Keywords

aldosterone antagonist angiotensin-converting enzyme inhibitor angiotensin receptor blocker beta-blocker digoxin diuretics elderly heart failure vasodilator

Get full access to this article

View all access options for this article.

References

Sultz

, Young

Health care USA: understanding its organization and delivery. 6th ed. Sudbury, MA: Jones and Bartlett Publishers, 2009:492.

Kalogeropoulos

, Georgiopoulou

, Kritchevskyet

. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. Arch Intern Med 2009;169:708–15. DOI 10.1001/archinternmed.2009.40

Dobre

, Veldhuisen

, Mordenti

. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 2007;154:109–15. DOI 10.1016/j.ahj.2007.03.025

Centers for Medicare and Medicaid. Medicare enrollment: national trends 1966–2008. www.cms.hhs.gov/MedicareEnRpts/Downloads/HI08.pdf (accessed 2010 Feb 18).

Lloyd-Jones

, Adams

, Camethonet

. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:21–181. DOI 10.1161/CIRCULATIONAHA.108.191261

Aronow

. Heart failure update: treatment of heart failure with a normal left ventricular ejection fraction in the elderly. Geriatrics 2006;61:16–20.

Kosiborod

, Lichtman

, Heidenreich

. National trends in outcomes among elderly patients with heart failure. Am J Med 2006;119:616 e1–7.

Curtis

, Whellan

, Hammill

. Incidence and prevalence of heart failure in elderly persons, 1994–2003. Arch Intern Med 2008;168:418–24. DOI 10.1001/archinternmed.2007.80

Croft

, Giles

, Pollard

, Keenan

, Casper

, Anda

. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999;159:505–10. DOI 10.1001/archinte.159.5.505

10.

Parashar

, Katz

, Smith

. Race, gender, and mortality in adults > or = 65 years of age with incident heart failure (from the Cardiovascular Health Study). Am J Cardiol 2009;103:1120–7. DOI 10.1016/j.amjcard.2008.12.043

11.

Disorders of the heart. Fauci

, Braunwald

, Kasper

, Hauser

, eds. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill, 2008:1444–56.

12.

Forman

, Rich

. Heart failure in the elderly. Congest Heart Fail 2003;9:311–23. DOI 10.1111/j.1527-5299.2003.00798.x

13.

Aronow

. Treatment of heart failure with abnormal left ventricular systolic function in the elderly. Clin Geriatr Med 2007;23:61–81. DOI 10.1016/j.cger2006.08.004

14.

Hunt

, Abraham

, Chin

. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391–479. DOI 10.1161/CIRCULATIONAHA.109.192065

15.

Flather

, Yusuf

, K⊘ber

. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575–81.

16.

Garg

, Yusuf

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450–6. DOI 10.1001/jama.273.18.1450

17.

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429–35.

18.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293–302.

19.

Cohn

, Johnson

, Ziesche

. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303–10.

20.

Tehrani

, Phan

, Chien

. Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction. Am J Cardiol 2009;103:829–33. DOI 10.1016/j.amjcard.2008.11.047

21.

Pitt

, Poole-Wilson

, Segal

. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582.

22.

Cohn

, Tognoni

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75. DOI 10.1056/NEJMoa010713

23.

McMurray

, Ostergren

, Swedberg

. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767–71. DOI 10.1016/S0140-6736(03)14283-3

24.

Granger

, McMurray

, Yusuf

. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–6. DOI 10.1016/S0140-6736(03)14284-5

25.

Foody

, Farrell

, Krumholz

. Beta-blocker therapy in heart failure: scientific review. JAMA 2002;287:883–9. DOI 10.1001/jama.287.7.883

26.

Avezum

, Tsuyuki

, Pogue

, Yusuf

Beta-blocker therapy for congestive heart failure: a systemic overview and critical appraisal of the published trials. Can J Cardiol 1998;14:1045–53.

27.

Lechat

, Packer

, Chalon

, Cucherat

, Arab

, Boissel

. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184–91.

28.

Doughty

, Rodgers

, Sharpe

, MacMahon

Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997;18:560–5.

29.

Heidenreich

, Lee

, Massie

. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27–34. DOI 10.1016/S0735-1097(97)00104-6

30.

Brophy

, Joseph

, Rouleau

. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001;134:550–60.

31.

Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). The International Steering Committee. Am J Cardiol 1997;80:54J–8J.

32.

Goldstein

Clinical studies on beta blockers and heart failure preceding the MERIT-HF trial. Metoprolol CR/XL Randomized Intervention Trial in Heart Failure. Am J Cardiol 1997;80:50J–3J.

33.

MERIT-HF Study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–7. DOI 10.1016/S0140-6736(99)04440-2

34.

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13. DOI 10.1016/S0140-6736(98)11181-9

35.

Packer

, Bristow

, Cohn

. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–55. DOI 10.1056/NEJM199605233342101

36.

Packer

, Coats

, Fowler

. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–8. DOI 10.1056/NEJM200105313442201

37.

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659–67. DOI 10.1056/NEJM200105313442202

38.

Cowie

, Fox

, Wood

. Hospitalization of patients with heart failure: a population-based study. Eur Heart J 2002;23:877–85. DOI 10.1053/euhj.2001.2973

39.

Kramer

, Curtis

, Dupree

. Comparative effectiveness of β-blockers in elderly patients with heart failure. Arch Intern Med 2008;168:2422–32. DOI 10.1001/archinternmed.2008.506

40.

, Jingrong

, Gurwitz

, Hus

, Lane

, Platt

Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. Arch Intern Med 2008;168:2415–21. DOI 10.1001/archinternmed.2008.511

41.

McAlister

, Wiebe

, Ezekowitz

, Leung

, Armstrong

. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784–94.

42.

Sin

, McAlister

. The effects of β-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med 2002;113:650–6. DOI 10.1016/S0002-9343(02)01346-3

43.

Erdmann

, Lechat

, Verkenne

, Wiemann

Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001;3:469–79. DOI 10.1016/S1388-9842(01)00174-X

44.

Deedwania

, Gottlieb

, Ghali

, Waagstein

, Wikstrand

. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004;25:1300–9. DOI 10.1016/j.ehj.2004.05.022

45.

Flather

, Shibata

, Coats

. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215–25. DOI 10.1093/eurheartj/ehi115

46.

Coats

. Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents. Drugs Aging 2006;23:93–9. DOI 10.2165/00002512-200623020-00001

47.

Cohen-Solal

, Kotecha

, Veldhuisen

. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 2009;11:872–80. DOI 10.1093/eurjhf/hfp104

48.

Dickstein

, Cohen-Solal

, Filippatos

. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933–89. DOI 10.10167/j.ejheart.2008.08.005

49.

Komajda

, Follath

, Swedberg

. The EuroHeart Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:464–74.

50.

Dugen

, Apostolovic

, Inkrot

. Bisoprolol vs carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol 2008;97:578–86.

51.

Sica

. Metolazone and its role in edema management. Cong Heart Failure 2007;9:100–5.

52.

Ahmed

, Young

, Love

, Levesque

, Pitt

A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol 2008;125:246–53. DOI 10.1016/j.ijcard.2007.05.032

53.

The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525–33. DOI 10.1056/NEJM199702203360801

54.

Neuberg

, Miller

, O'connor

. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31–8. DOI 10.1067/mhj.2002.123144

55.

Aronow

. Treatment of systolic and diastolic heart failure in the elderly. J Am Med Dir Assoc 2006;7:29–36. DOI 10.1016/j.jamda.2005.07.008

56.

Sica

, Gehr

, Frishman

. Use of diuretics in the treatment of heart failure in the elderly. Clin Geriatr Med 2007;23:107–21. DOI 10.1016/j.cger.2006.08.006

57.

Barr

, Lang

, Hanson

, Arnott

, Kennedy

, Struthers

. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259–65. DOI 10.1016/S0002-9149(99)80353-1

58.

MacFadyen

, Barr

, Struthers

. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30–4. DOI 10.1016/S0008-6363(97)00091-6

59.

Rietzschel

, Duprez

, Buyzere

, Clement

. Inverse relation between aldosterone and venous capacitance in chronically treated congestive heart failure. Am J Cardiol 2000;85:977–80. DOI 10.1016/S0002-9149(99)00913-3

60.

Guglin

, Awad

, Polavaram

, Vankayala

Aldosterone antagonists: the most underutilized class of heart failure medications. Am J Cardiovasc Drugs 2007;7:75–9. DOI 10.2165/00129784-200707010-00007

61.

Trujillo

, Gonyeau

, DiVall

, Alexander

. Spironolactone use in patients with heart failure. J Clin Pharm Ther 2004;29:165–70. DOI 10.1111/j.1365-2710.2004.00549.x

62.

Dunlap

. New studies influencing treatment of heart failure: 2006 update. Pharmacotherapy 2007;27(4 pt 2):3S–11S. DOI 10.1592/phco.27.4part2.3S

63.

Pitt

, Zannad

, Remme

. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–17. DOI 10.1056/NEJM199909023411001

64.

Juurlink

, Mamdani

, Lee

. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543–32.

65.

Pitt

, Williams

, Remme

. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79–87. DOI 10.1023/A:1011119003788

66.

Pitt

, Remme

, Zannad

. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–21. DOI 10.1056/NEJMoa030207

67.

Rathore

, Curtis

, Wang

, Bristow

, Krumholz

. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871–8. DOI 10.1001/jama.289.7.871

68.

Ahmed

, Rich

, Love

. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178–86. DOI 10.1093/eurheartj/ehi687

69.

Chun

, Chodosh

Controversy in heart failure management: digoxin use in the elderly. J Am Med Dir Assoc 2006;7:581–6. DOI 10.1016/j.jamda.2006.08.010

70.

Cheng

. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clin Ther 2006;28:666–78. DOI 10.1016/j.clinthera.2006.05.007

71.

Taylor

, Ziesche

, Yancy

. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–57. DOI 10.1056/NEJMoa042934

72.

Jolobe

. Evaluation of renal function in elderly heart failure patients on ACE inhibitors. Postgrad Med J 1999;75:275–7.

73.

Mascarenhas

, Lourenco

, Lopes

, Azevedo

, Bettencourt

Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 2008;155:521–5. DOI 10.1016/j.ahj.2007.10.040

74.

Guck

, Elsasser

, Kavan

, Barone

. Depression and congestive heart failure. Congest Heart Fail 2003;9:163–9. DOI 10.1111/j.1527-5299.2003.01356.x